and CXCL11 bind to the canonical receptors CXCR4 and CXCR3, respectively. Here, we present the engineering of a chemokine-like chimera, which selectively binds to ACKR3. The addition of a ybbR13 tag at the C-terminus allows site specific enzymatic labeling with a plethora of fluorescent dyes. The chimera is composed of the N-terminus of CXCL11 and the main body and C-terminus of CXCL12 and selectively interacts with ACKR3 with high affinity, while not interfering with binding of CXCL11 and CXCL12 to their cognate receptors. We further provide evidence that the chimera can be used to study ACKR3 function in vivo.
INTRODUCTION
Chemokines and their cognate chemokine receptors constitute the chemokine system, which principally orchestrates leukocyte trafficking during homeostasis and inflammation. The system is also involved in development and has a key role in cancer growth and metastasis. 1 Typical pertussis toxin-sensitive chemokine receptors, members of the rhodopsin like family of G-protein coupled receptors (GPCRs), activate diverse intracellular signaling cascades and commonly trigger cell migration. In addition to the "typical" or "canonical" receptors, chemokines also bind to atypical chemokine receptors (ACKRs). ACKRs are heptahelical membrane proteins, structurally homologous and phylogenetically related to canonical chemokine Abbreviations: ACKR, atypical chemokine receptor; GPCR, G-protein coupled receptor; HPF, high power field; IMAC, immobilized-metal affinity chromatography; MFI, mean fluorescence intensity; PFA, paraformaldehyde germ cell requires ACKR3 expression. 3, 4 The scavenging acitivity of ACKR3 expressed on stroma cells is required to maintain CXCL12 gradients for directed migration of the germ cells. 4, 5 In addition, the cells of the primordium express CXCR4 and ACKR3 at the anterior and posterior side, respectively, creating CXCL12 gradients. 6, 7 During mouse brain development ACKR3 controls the levels of CXCL12 to promote the CXCR4-dependent outgrowth of interneurons. 8 Under inflammatory conditions ACKR3 is upregulated at the basal site of brain microvessel endothelium scavenging perivascular CXCL12, thereby abolishing the perivascular retention of CXCR4 + leukocytes and indirectly promoting their entry into the parenchyma. 9 Using a disseminated xenograft model, we recently reported that the diffuse large B cell lymphoma Val cells require ACKR3 expression for organ infiltration. In vitro ACKR3 expression by these cells was required for efficient CXCL12-induced CXCR4-dependent chemotaxis. 10 Ectopic expression of overexpressed ACKR3 and CXCR4 was suggested to result in heterodimerization, which altered CXCR4-dependent signaling. 11 Both receptors, ACKR3 and CXCR4, are broadly expressed on hematopoietic and mesenchymal cells. 1, 12, 13 The second ligand of ACKR3 is CXCL11, an IFN-inducible chemokine.
CXCR3 binds CXCL11 with high affinity (apparent K d ∼ 1 nM) 14 and is expressed on various lymphocytes. 1 Targeted gene deletion of ACKR3 revealed a key role of the receptor in development, as deficient mice are not viable displaying a marked cardiac phenotype with stenotic defects in heart valves and vessels. Interestingly, the mouse strain used for target deletion C57BL/6 is deficient in CXCL11, hence the phenotype was ascribed to the abolished interaction of ACKR3 with CXCL12. 15 One chemokine can bind several receptors and a receptor can bind multiple chemokines. 1 Given this promiscuity of the chemokine system, delineating the specific activity of a chemokine receptor pair in vivo is challenging. It is therefore valuable to engineer structurally related chemokines which specifically target a single receptor, in order to study ligand-receptor interactions in complex biological systems.
About 50 human chemokines have been characterized. They are small proteins (8-10 kD) with highly diverse primary sequences, but share structural homology dictated by 4 conserved cysteines forming two characteristic disulfide bridges. According to the two step binding model 16 the rigid loop (also called N-loop) with an overall basic charge downstream of the first two cysteines mediates the initial binding to the negatively charged N-terminus of the receptors. Whereas the flexible N-terminus of chemokines inserts into the binding pocket of the receptors triggering conformational changes which translate in intracellular signaling. In line with this, modifications of the N-terminus often result in altered receptor activation leading to either loss of function or enhanced potency and/or efficacy. Three beta strands and the short helix present at the C-terminus of most chemokines harbor glycosaminoglycan (GAG) binding sites for presentation of chemokines on cell surfaces, which is required for haptotatic migration of cells. 17 Binding and retention of chemokines on cell surfaces or the extracellular matrix is critical for the formation of locally confined chemotactic gradients. 18 However, the interactions of chemokines with GAGs is not uniform and can fine-tune the function of chemokines. 19 
CXCL12
possesses one GAG binding site in its first -strand 20, 21 and differs therein from CXCL12 and particularly CXCL12 , which harbor additional GAG binding sites at their extended C-termini. 22, 23 In solution, CXCL12 can form dimers depending on the environmental conditions, such as pH and heparin. 24 Monomeric and dimeric forms of CXCL12 were shown to bind and to induce signal bias on CXCR4, where dimeric CXCL12 poorly recruits arrestin and essentially does not stimulate cell migration. 25, 26 ACKR3 binds preferentially monomeric CXCL12 27 with about 10-fold higher affinity than CXCR4 (apparent K d for ACKR3 ∼ 0.3 nM). 28, 29 The affinity of CXCL11, the second chemokine ligand of ACKR3, is somewhat lower (2-5 nM). 29 CXCL11 and CXCL12 share at most 20% of their primary sequences including the 4 conserved cysteines. The N-termini preceding the first cysteine of both chemokines have the same length, but share only the amino acids at position 2 (proline; P, one letter code) and 8 (arginine; R). Currently no crystal structure of ACKR3 is available, however extensive radiolytic footprinting revealed contact points between CXCL12 and ACKR3. Comparing the sequences of CXCL11 and CXCL12 with the data from the radiolytic footprinting suggests that different domains of ACKR3 must be involved in the recognition of the 2 chemokines. 30 A recent study confirmed different modes of binding of CXCL11 and CXCL12 to ACKR3. 31 CXCL11 induced a faster ACKR3 internalization, but slower recycling than CXCL12. Moreover, the authors suggest that arrestin binding to ACKR3 is not required for chemokine scavenging. 31 The finding somewhat contrasts other observations where it was shown that CXCL11 and CXCL12 binding to ACKR3 enhances arrestin recruitment. [32] [33] [34] [35] [36] A known drawback for the investigations of GPCRs is the paucity of antibodies which recognize endogenous receptors expressed at the cell surface. Alternatively, chemokine receptor surface expression and function was successfully measured with fluorescent labeled chemokines. 10, [37] [38] [39] [40] The specificity of this approach is limited by the promiscuity of the chemokine system, in addition chemokines are internalized through the scavenging activity of atypical receptors.
Nevertheless, fluorescent chemokines can also be used in vivo to reveal receptor localization and function. 41 There are no selective chemokines for ACKRs because its cognate chemokines bind at least to one canonical receptor. Here, we describe the engineering of a novel chimeric chemokine combining CXCL11 and CXCL12, which is a selective ligand for ACKR3 and, by analogy to CXCL12, is monomeric and has reduced GAG binding ability. The chimera was in addition tagged at the C-terminus with an acyl carrier protein tag for site specific enzymatic labeling with fluorophores. 40, 42, 43 The high affinity of the chimera for ACKR3 allows to reveal sites of functional ACKR3 expression in vivo.
MATERIALS AND METHODS

Cells
Mouse 300.19 pre-B cells were cultured in B cell medium (RPMI-1640 supplemented with 10% FBS, 1% PenStrep, 1% nonessential amino acids, 1% Glutamax, and 50 M -mercapto ethanol ( -ME)). CEM cells were cultured in T cell medium (RPMI-1640 supplemented with 10% FBS, 1% PenStrep, and 1% Glutamax). HeLa cells were maintained in high glucose DMEM (4.5 g/l) supplemented with 10% FBS and 1%
PenStrep. All cell culture media and supplements were from Thermofisher. Transient transfections with plasmids containing an internal ribosomal entry side encoding for chemokine receptors CXCR4, CXCR3, or ACKR3 and EGFP were performed with 500 ng DNA added to 1 l Lipofectamine LTX and 0.5 l PLUS reagent (Thermofisher) per glass-bottom Petri dish (MatTek). Cells were left overnight and inspected for GFP expression prior to experimental usage. Bone marrow cells from WT and ACKR1-deficient mice were prepared as described elsewhere. 44 
Chemokine expression and purification
Recombinant chemokines were expressed in E. coli as previously described. 42 Briefly, chemokine sequences were preceded by an enhancer GroE sequence, followed by an 8-H encoding sequence, 2 amino acids (LE), and the enterokinase recognition site (DDDDK). 45 When indicated to the C-terminus of the chemokine the ybbR13 (DSLEFIASKLA) sequence was fused to allow site specific labeling with phosphopantetheinyl transferase. 43 Chemokines were purified from inclusion bodies by immobilized-metal affinity chromatography (IMAC) and refolded under N 2 protection in an arginine containing buffer (80 mM Tris-Cl (pH 8.5), 100 mM NaCl, 0.8 M arginine, 2 mM EDTA, 1 mM cysteine, 0.2 mM cystine). After recovery and concentration the N-terminus was cleaved with enterokinase and chemokines purified by C 18 reverse phase chromatography.
Chemokines were labeled with phosphopantetheinyl transferase (Sfp) (New England Biolabs), fluorescent labeled CoA. 42, 46 Briefly, ybbR13-tagged chemokines (10 M) were incubated overnight at room temperature in the dark in 20% glycerol, 100 mM NaCl, 10 mM 
Chemokine uptake assay by confocal microscopy
Uptake of fluorescent labelled chemokines was measured in transiently transfected HeLa cells incubated for 45 min at 37 • C in OptiMem containing 50 nM CXCL11_Atto565, CXCL12_Atto565, and CXCL11_12_Atto565. Cells were washed in warm PBS, fixed in 4% paraformaldehyde (PFA) in PBS for 20 min at room temperature, stained with DAPI (0.1 g/ml PBS) for 5 min and washed with PBS.
Cells were imaged with a laser scan confocal microscope (Leica SP5) and images analyzed using Imaris software (Bitplane).
Chemotaxis assays were performed using 48-well modified Boyden chambers (AP48, NeuroProbe) as previously described. 48 CEM cells (100,000/well) were allowed to migrate for 90 min at 37 • C in an incubator (5% CO 2 ) toward increasing concentrations of chemokine 
RESULTS
For determining the surface expression and scavenging activity of ACKR3 a specific endogenous ligand is missing. CXCL11 and CXCL12 both bind to ACKR3, but also to their cognate receptors CXCR3 or CXCR4, respectively, making it difficult to reveal the expression and function of the atypical receptor in the presence of the canonical receptors. AMD3100 was described as selective inhibitor of CXCR4, which blocks binding and CXCL12-mediated signaling 49, 50 and could be used to discriminate between CXCR4 and ACKR3-dependent CXCL12 internalization. However, at full effective concentrations AMD3100 also targets ACKR3. 31, 51 Binding of CXCL11 to CXCR3 can be similarly abolished with small molecule inhibitors, however, ACKR1 also binds the chemokine potentially obscuring interactions with ACKR3. 1 In order to design a selective ligand for ACKR3, we hypothesized that a chimeric chemokine composed of domains derived from CXCL11 and CXCL12 could possess such characteristic. Modification or truncation of the N-terminus of CXCL12 markedly affects its affinity for CXCR4. 16 Exchange of proline 2 with glycine on CXCL12 (P2G-CXCL12) turns the chemokine into an antagonist that binds CXCR4 with similar affinity as the wild type counterpart, but does not induce signaling. 16, 52 To test a possible effect of substitutions at the Nterminus of CXCL12 for its ability to bind to ACKR3 we took advantage of an in house available fluorescent fusion protein P2G-CXCL12-YFP, which bound to CXCR4 expressing MDCK cells, and as expected, did not induce signaling. 16, 52 However, the fusion protein was readily internalized by MDCK cells transiently expressing ACKR3, suggesting that the substitution of the critical proline at the N-terminus did not abolish scavenger activity (not shown). On the other hand truncation of the N-terminus of CXCL12 was reported to markedly reduce its binding to ACKR3, 28 suggesting that the domain plays some role in chemokine recognition.
Chimeric construct
Considering that ACKR3 binds CXCL12 and CXCL11, we designed a chimeric chemokine consisting of the 8 amino acids of the N-terminus of CXCL11 and the body of CXCL12 starting with the common arginine 8 preceding the first cysteine 9 of the CXC motif (Fig. 1) . The first -strand of CXCL12 contains a BBXB (B for basic amino acid and X any amino acid) motif comprising lysine (K) 24 , histidine (H) 25 , and lysine (K) 27 which promotes GAG binding 21, 53 together with lysine (K) 41 located on the second -strand. 54 In order to reduce GAG interactions, which could lead to background signals when ACKR3 binding is imaged in tissues, we substituted these residues by exchanging K 24 , K 27 , and K 41 for serine (S) at all positions. Replacing histidine 25 with arginine at the potential dimerization interface was shown to shift the equilibrium to the monomeric state of CXCL12 , 24 which is the favored state for the chemokine to bind ACKR3. 27 Figure 1 depicts the modifications in the first and second -strand. We fused a tag for site specific enzymatic labeling to lysine (K) 68 located at the extreme C-terminus of CXCL12 , based on the notion that modifications of the C-terminus have minor effects on chemokine receptor binding. 40, 42 We chose a short peptide tag for orthogonal protein labeling with phosphopantetheinyl transferase, which was fused to the palindrome sequence for BsiW1 (encoding for RT) allowing cassette cloning of chemokines. The 11 amino acid-long ybbR13 sequence (DSLEFI-ASKLA) was derived from B. Subtilis peptidyl carrier protein and is targeted by phosphopantetheinyl transferase Sfp from B. subtilis. 43, 55 The affinity of the tag for the Sfp enzyme is 123 M permitting an efficient modification of the serine residue at position 2 of the ybbR13 sequence with conjugated CoA as substrate. 43, 56 We selected the ybbR13sequence because this consensus sequence is less hydrophobic compared with other motives and has a reasonably high affinity for the B. Subtilis enzyme Sfp. 43, 57 Fusing more hydrophobic sequences with higher affinity for Sfp to the C-termini of chemokines caused their tendency to aggregate (not shown). The relative insensitivity of phosphopantethenyl transferases for modifications at the free sulfhydryl group of CoA allows to site specific label tagged chemokines with almost any low molecular weight fluorophore. 42, 46 The full name of the chimeric chemokine, CXCL11_12 H25R Gag − ybb13, reconciles all these features, for convenience, we use here the short form CXCL11_12 followed by the fluorophore linked to the ybbR13 tag.
We expressed CXCL11_12 in E.Coli with an His-tag and the enterokinase consensus sequence at the N-terminus 42 
Binding and specific uptake of CXCL11_12
First, we tested the binding of CXCL11, CXCL12, and CXCL11_12 to pre-B cells transfected with human CXCR3, CXCR4, and ACKR3 at 4 • C. Under these conditions receptor endocytosis is blocked and chemokines bind only to cell surface expressed receptors. As expected, Supplementary Fig. 1 shows that CXCL11 bound to CXCR3 and ACKR3 expressing cells, but only marginally to CXCR4 + cells. Contrariwise, CXCL12 only bound to CXCR4 and ACKR3 expressing cells. The chimera was found to associate with ACKR3 and CXCR4 expressing cells and marginally to CXCR3. Binding to CXCR4 is in agreement with the reported low affinity binding of CXCL12 variants with truncated N-termini. 16 The selectivity of the chimeric chemokine for ACKR3 was tested through uptake by mouse pre-B 300.19 cells at 37 • C. The parental cell line is known to not express either receptor. Figure 2A To test a potential interaction of CXCL11_12 with ACKR1, we isolated bone marrow from wild type and ACKR1-deficient mice. Cell suspensions were analyzed by flow cytometry gating for nucleated erythrocyte cells using transferrin (CD71) and the erythrocyte lineage marker Ter119. 58 The double positive cells from wild type animals express high surface levels of ACKR1. 44 Figure 2B shows that cells from wild type or ACKR1-deficient animals neither bound nor internalized CXCL11_12 during incubation at 37 • C for 1 h.
To confirm the uptake of chemokines we transiently expressed either human or mouse CXCR3, CXCR4, and ACKR3 together with GFP in Hela cells and revealed uptake by confocal microscopy. (not shown).
We determined the affinity of the chimera for ACKR3 using com- is negligible (not shown) . 59, 60 Similarly, CXCL11 and CXCL12 competed binding of CXCL11_12 Alexa647 with similar kinetics. Consistent with the specificity of CXCL11 and CXCL12 for ACKR3 a highly promiscuous chemokine CCL5, which binds several chemokine receptors namely CCR1,2,3, 5 1 did not compete CXCL11_12 binding.
Chemotaxis
We next tested possible effects of the chimera on CXCL11 and CXCL12-mediated chemotaxis through their cognate receptors CXCR3 and CXCR4, respectively. The T cell line CEM which expresses high surface levels of endogenous CXCR4 was used in Boyden chamber chemotaxis assays. Figure 5 depicts a typical bell-shaped dose response curve of CEM cell chemotaxis in response to CXCL12 with a peak migration at about 3 nM. An almost identical migratory behavior was observed, when we performed the assay in the presence of 10 nM CXCL11_12 in both, the upper and lower compartment, suggesting no interference of the chimera with CXCL12 binding to CXCR4. Similarly, we tested the chemotactic responsiveness of CXCR3-transfected 
CXCL11_12 in vivo
ACKR3 is known to be expressed on vascular endothelium and to act there as a scavenger for CXCL12, 15, 61 In fact systemic inhibition of ACKR3 with small molecules leads to elevated CXCL12 serum levels. 62 Expression of ACKR3 on heart endothelium appears to have a key role during embryonal development. 15 To test our chimera in 
DISCUSSION
Specific targeting of atypical chemokine receptors is challenging due to the promiscuity of their ligands which all bind also to at least one canonical chemokine receptor. The two ligands of ACKR3, CXCL11, and CXCL12, bind CXCR4 and CXCR3 respectively, induce their internalization and are therefore not specific for ACKR3. The atypical receptor does not couple to G-proteins and little is known about specific downstream signaling that could be used to reveal its activity in vivo using endogenous ligands. We engineered a selective fluorescent labeled chemokine-like ligand and show that it can be used to reveal receptor scavenging activity in vivo.
The promiscuity and lack of ligand-induced coupling to G-proteins suggest that atypical chemokine receptors are less sensitive than typical receptors to alterations of the N-terminus of chemokines.
We exchanged the N-terminus of CXCL12 with the corresponding amino acids derived from CXCL11, driven by the notion that CXCR4 is particularly sensitive to modifications of the N-terminus of CXCL12. 16 A recent study suggests that chemokine binding and activation of ACKR3 differs significantly from that of the typical receptors CXCR3 F I G U R E 5 Effect of CXCL11_12 on CXCL12 mediated chemotaxis. Human CEM T cells expressing endogenous CXCR4 were allowed to migrate towards increasing concentrations of CXCL12 in modified Boyden chambers. When indicated (closed symbols) 10 nM CXCL11_12 was added to the upper and lower compartment. Migrated cells were counted from 5 randomly selected high power fields (HPF) of triplicates at 100x magnification. Typical experiment from 3 independent mesurements and CXCR4. 36 In their study, the authors used peptides derived from the N-termini of CXCL11 and CXCL12, to show different binding and activation potencies depending of amino acid substitutions. However, contrarily to our chimeric chemokine, which has comparable affinity to ACKR3 as the natural ligands, the peptides have a markedly lower affinity (100-2000-fold) for ACKR3. 36 It is conceivable and in line with radiolytic footprinting analysis of CXCL12:ACKR3 complexes, that both the N-terminus and the body constitute together the high affinity binding to ACKR3. 30 The putative GAG binding site in the rigid loop of CXCL11_12 is most likely not involved in ACKR3 binding. The assumption is again deduced from the radiolytic footprinting analysis of CXCL12:ACKR3 complexes where amino acids 21-26 were shown to not interact with ACKR3. 30 Hence, mutation of the GAG binding sites should reduce the retention of the chimera on proteoglycans, without altering binding to ACKR3. Similarly, the point mutation of histidine 25 to arginine, that was reported to render CXCL12 monomeric, 24 should not attenuate rather enhance the interaction with ACKR3, which preferably binds CXCL12 monomers. 27 Competition of CXCL11_12 binding to ACKR3 revealed similar affinities for CXCL11 and CXCL12 and for the chimera itself (Fig. 4) .
The data appear to contrast the uptake of the chemokines by ACKR3 expressing cells (Fig. 2) , where the chimera appears to be less efficiently internalized. It is plausible that chemokine uptake not only depends on their specific affinity, but also on the possible (biased) stimulatory capacity that modulates the scavenging activity.
Our FACS and microscopy analyses clearly indicate that CXCL11_12 is a selective chemokine-like ligand which binds ACKR3 with high affinity and is readily internalized by the scavenger. These properties render the chimeric chemokine an ideal tool to study expression and function of the receptor. Indeed i.v. injection of CXCL11_12 into live mice revealed its expected uptake by heart 
